RESOLVING THE LEDGER
This is one outlet's own report from Newsweek — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 1 sources
0 Share Newsweek is a Trust Project member See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. GSK cancer drug Jemperli has been granted priority review by the U.S. Food and Drug Administration ( FDA ) after a pivotal trial showed no detectable signs of rectal tumors for at least one year in a significant proportion of patients.
The move signals a potentially historic shift in how certain rectal cancers are treated. If approved, the drug could allow selected patients to avoid chemotherapy, radiation and surgery, reshaping first‑line care for a disease long defined by invasive treatment .
The FDA set a February 2027 decision deadline, but the application also qualifies for accelerated consideration under the National Priority Voucher program, meaning an earlier ruling is possible. The submission is also being reviewed through Project Orbis, which opens the door to coordinated international approvals.
The FDA’s review is based on AZUR‑1, a global phase II trial evaluating Jemperli as a standalone treatment for previously untreated stage II/III dMMR/MSI‑H locally advanced rectal cancer. The study met its primary endpoint by demonstrating clinical complete responses lasting at least 12 months.
“The headline results showed that AZUR‑1 met its primary objective by demonstrating meaningful and sustained clinical complete responses for 12 months [cCR12], meaning no detectable signs of cancer for at least one year,” Hesham Abdullah, GSK senior vice president and global head of oncology R&D told Newsweek . “AZUR‑1 results show a substantial improvement in cCR12 when compared to the historical standard of care.”
The trial enrolled 154 patients, all of whom received nine cycles of Jemperli over six months. Interim safety findings were consistent with the drug’s established profile.
“In interim data, the safety and tolerability profile of dostarlimab was generally consistent with its well‑characterized and manageable safety profile observed across solid tumors,” Abdullah said.
“Traditional treatment of stage II and III dMMR/MSI‑H locally advanced rectal cancer has been chemotherapy plus radiation followed by surgery,” Abdullah said. “Although the traditional treatments are delivered with curative intent, they often lead to long‑term negative quality‑of‑life impacts… and nearly one‑third of patients ultimately die from cancer that has spread to other parts of the body.
“Jemperli could become the first approved immunotherapy capable of helping some patients with locally advanced rectal cancer eliminate or delay the need for chemotherapy, radiation and surgery."
The possibility of avoiding surgery—and the irreversible consequences that often follow—is one of the most consequential aspects of the AZUR‑1 findings. Abdullah said the current standard, while often effective, comes with a steep personal cost for many patients.
“While these traditional treatments result in initial positive outcomes for most patients, the sacrifice in quality of life is profound and often underestimated,” he said.
He pointed to the long‑term burdens patients routinely face after chemoradiation and surgery.
“Depend on life‑long use of a colostomy bag, which can be associated with physiological [bowel, urinary, sexual] dysfunction, psychological distress, social stigma and additional health complications,” he said.
Patients may also “experience issues with fertility, which is lost during chemo‑radiation,” along with “other debilitating treatment‑related side effects related to bowel, urinary, sexual, and body‑image consequences, which can take a major toll on day‑to‑day lives.”
If Jemperli becomes a first‑line option, Abdullah said, these outcomes could be avoided for selected patients.
The AZUR‑1 results build on earlier work from Memorial Sloan Kettering Cancer Center, which first demonstrated that PD‑1 blockade could produce complete responses without chemoradiation.
“dMMR/MSI‑H tumors tend to carry a large number of genetic changes, and those changes can make the cancer more visible to the immune system,” Abdullah said. “As a result, these tumors often have more immune cells already present and trying to attack them.”
He explained how Jemperli amplifies that response: “Anti‑PD‑1 immunotherapies such as Jemperli work by taking the ‘brakes’ off those immune cells, helping them mount a stronger attack against the cancer. That is why identifying dMMR/MSI‑H through biomarker testing can be so important…although it does not guarantee that every patient will respond.”
The FDA has set a February 2027 PDUFA date, but the application’s eligibility for the National Priority Voucher program could mean a decision comes earlier. GSK is also pursuing approval through Project Orbis, enabling simultaneous review by international regulators.
Abdullah said the National Priority Voucher “provides for an expedited review process, so FDA action could occur ahead of that date,” though he declined to speculate beyond the agency’s stated timelines. The combination of priority review, Fast Track designation, Breakthrough Therapy designation, and Orbis participation underscores the urgency of bringing new options to patients with limited alternatives.
If approved, Jemperli would become the first immunotherapy capable of eliminating or delaying chemotherapy, radiation and surgery for some patients with this subtype of rectal cancer. Clinicians would need to incorporate biomarker testing earlier in the diagnostic process, and treatment pathways could shift toward immunotherapy‑first strategies.
The biopharma company’s oncology portfolio has expanded significantly in recent years, with Jemperli serving as a backbone of its immuno‑oncology strategy. The company’s shares have risen 9.7 percent year‑to‑date, reflecting investor confidence in its pipeline.
Abdullah said the AZUR‑1 milestone “is an essential step in bringing scientific innovation to patients,”...
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.